CI

At a glance

ClinicalIndex Comparison Record
Phase 2Active· 7 enrolled
Drug / intervention
Bavituximab +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04150900
NCT04150900Phase 2Active
CompareCT.gov

1922GCCC: PHASE 2 STUDY OF PEMBROLIZUMAB AND BAVITUXIMAB FOR PROGRESSIVE RECURRENT/METASTATIC SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK

University of Maryland, Baltimore·interventional·Posted Nov 5, 2019·Updated Feb 19, 2026

In Brief

A Phase 2 clinical trial evaluating Bavituximab and Pembrolizumab for Squamous Cell Carcinoma. Active but no longer recruiting, targeting 7 participants across 1 site.

Detailed Summary

This phase II single arm study is being done to determine if bavituximab could potentially synergize with PD-1 inhibitor therapy to generate an effective anti-tumor immune response in patients with recurrent/metastatic squamous cell head and neck cancer (HNSCC) who progressed on a PD-1 inhibitor.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSquamous Cell Carcinoma
CountriesUnited States
Collaborators--

Timeline

Phase 2Active
20202021202220232024202520262027
First PostedNov 5, 2019
Enrollment StartJan 13, 2020
Primary CompletionSep 1, 2024
Study CompletionJan 1, 2027
TodayJul 2, 2026
Enrollment to primary: 4.6 yearsPosted 6.7 years ago

Interventions

Bavituximabdrug

Bavituximab is a chimeric (human/mouse) monoclonal antibody (mAb) derived from murine mAb 3G4 that targets phosphatidylserine (PS) after binding to β2-glycoprotein 1 (β2-GP1).

Pembrolizumabdrug

Pembrolizumab is a highly selective humanized mAb designed to block the interaction between PD-1 and its ligands, PD-L1 and PD-L2.